These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 10583313

  • 1. Iopanoic acid-induced decrease of circulating T3 causes a significant increase in GH responsiveness to GH releasing hormone in thyrotoxic patients.
    Ramos-Dias JC, Lengyel AM.
    Clin Endocrinol (Oxf); 1999 Oct; 51(4):461-7. PubMed ID: 10583313
    [Abstract] [Full Text] [Related]

  • 2. Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis.
    Nascif SO, Senger MH, Ramos-Dias JC, Lengyel AM.
    J Endocrinol Invest; 2003 Aug; 26(8):733-7. PubMed ID: 14669827
    [Abstract] [Full Text] [Related]

  • 3. Low circulating IGF-I levels in hyperthyroidism are associated with decreased GH response to GH-releasing hormone.
    Ramos-Dias JC, Yateman M, Camacho-Hübner C, Grossman A, Lengyel AM.
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):583-9. PubMed ID: 8548943
    [Abstract] [Full Text] [Related]

  • 4. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
    Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R.
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
    [Abstract] [Full Text] [Related]

  • 5. Effects of methimazole treatment on growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism.
    Giustina A, Ferrari C, Bodini C, Buffoli MG, Legati F, Schettino M, Zuccato F, Wehrenberg WB.
    Acta Endocrinol (Copenh); 1990 Dec; 123(6):613-8. PubMed ID: 2284886
    [Abstract] [Full Text] [Related]

  • 6. Influence of hyperthyroidism on growth hormone secretion.
    Valcavi R, Dieguez C, Zini M, Muruais C, Casanueva F, Portioli I.
    Clin Endocrinol (Oxf); 1993 May; 38(5):515-22. PubMed ID: 8330446
    [Abstract] [Full Text] [Related]

  • 7. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
    [Abstract] [Full Text] [Related]

  • 8. Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
    Pinto AC, Finamor FE, Lengyel AM.
    Clin Endocrinol (Oxf); 1999 Oct; 51(4):409-14. PubMed ID: 10583306
    [Abstract] [Full Text] [Related]

  • 9. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
    Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
    [Abstract] [Full Text] [Related]

  • 10. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.
    Pimentel-Filho FR, Ramos-Dias JC, Ninno FB, Façanha CF, Liberman B, Lengyel AM.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):295-300. PubMed ID: 9156038
    [Abstract] [Full Text] [Related]

  • 12. Effects of three-day oral cholecystography on serum iodothyronines and TSH concentrations: comparison of the effects among some cholecystographic agents and the effects of iopanoic acid on the pituitary-thyroid axis.
    Suzuki H, Kadena N, Takeuchi K, Nakagawa S.
    Acta Endocrinol (Copenh); 1979 Nov; 92(3):477-88. PubMed ID: 517049
    [Abstract] [Full Text] [Related]

  • 13. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [Abstract] [Full Text] [Related]

  • 14. Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone.
    De Marinis L, Mancini A, Valle D, Bianchi A, Gentilella R, Liberale I, Mignani V, Pennisi M, Della Corte F.
    Clin Endocrinol (Oxf); 1999 Jun; 50(6):741-7. PubMed ID: 10468946
    [Abstract] [Full Text] [Related]

  • 15. Diurnal variations of plasma growth hormone, thyrotropin, thyroxine, and triiodothyronine in streptozotocin-diabetic and food-restricted rats.
    Ortiz-Caro J, González C, Jolin T.
    Endocrinology; 1984 Dec; 115(6):2227-32. PubMed ID: 6238818
    [Abstract] [Full Text] [Related]

  • 16. Effect of Iopanoic acid on the pituitary-thyroid axis: time sequence of changes in serum iodothyronines, thyrotropin, and prolactin concentrations and responses to thyroid hormones.
    Suzuki H, Noguchi K, Nakahata M, Nakagawa S, Kadena N.
    J Clin Endocrinol Metab; 1981 Oct; 53(4):779-83. PubMed ID: 6793610
    [Abstract] [Full Text] [Related]

  • 17. Different growth hormone (GH) response to GH-releasing peptide and GH-releasing hormone in hyperthyroidism.
    Ramos-Dias JC, Pimentel-Filho F, Reis AF, Lengyel AM.
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1343-6. PubMed ID: 8636330
    [Abstract] [Full Text] [Related]

  • 18. Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children.
    Portes ES, Oliveira JH, MacCagnan P, Abucham J.
    Clin Endocrinol (Oxf); 2000 Aug; 53(2):183-9. PubMed ID: 10931099
    [Abstract] [Full Text] [Related]

  • 19. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
    Micic D, Popovic V, Kendereski A, Peino R, Dieguez C, Casanueva FF.
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of intrapituitary thyroxine to 3.5.3'-triiodothyronine conversion prevents the acute suppression of thyrotropin release by thyroxine in hypothyroid rats.
    Larsen PR, Dick TE, Markovitz BP, Kaplan MM, Gard TG.
    J Clin Invest; 1979 Jul; 64(1):117-28. PubMed ID: 447848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.